Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of vosoritide in children with achondroplasia
2015-003836-11Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in achondroplasia (ACH) comparing Vosoritide with Placebo (2 arms). Primary endpoint: Change from baseline in annualized growth velocity. Started Oct 2016; status: completed.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2015-003836-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003836-11.